Previous 10 | Next 10 |
HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE PR Newswire WAKIX ® (pitolisant) Preliminary Net Revenue of ~$168 Million for Fourth Quarter ...
HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire PLYMOUTH MEETING, Pa. , Jan. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated...
2024-01-02 18:38:00 ET 2024 didn't exactly get off to a roaring start for Harmony Biosciences Holdings (NASDAQ: HRMY) stock. The neurology-focused biotech's shares took a nearly 5% hit on Tuesday, the first trading day of the year. The culprit was a recommendation downgrade from a p...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
2024-01-01 07:20:00 ET Summary My 2023 picks outperformed (by a factor of 2X) the benchmark VTI. I've managed to beat the market by an average of 3.7% per year over the past 10 years. Since I began using this list with clients in 2000, I’ve beaten the market by an average o...
2023-12-27 12:41:31 ET Summary Harmony Biosciences Holdings, Inc. is facing challenges including a failed Phase 3 study, doubts about its patent estate, and competition from rivals. The company's drug, Wakix, has been successful in generating revenue, but its monopoly is being cha...
2023-12-17 12:03:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the ...
2023-12-15 15:54:00 ET Summary The healthcare sector valuation is close to 11-year averages. Pharmaceuticals/biotechnology and life science tools are close to the historical baseline, while healthcare equipment is the less attractive subsector. iShares Global Healthcare ETF is...
2023-12-13 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1 Clinically meaningful improvements demonstrated in excessive daytime sleepiness and fatigue PR Newswire PLYMOUTH...
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
Harmony Biosciences Holdings Inc. Website:
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) PR ...
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY WAKIX is the first-and-only FDA-approved non-scheduled treatment option for excessive daytime sleepiness in pediatric patients 6 years of age and ol...